Value-added product contribution
5%
+0% YoY
Contribution of high-margin value-added products to total portfolio; expected to double to 10-12% in FY27.
VIDHISPECIALTYFOODINGRED
Consumer
15 May 2026
Vidhi Specialty Food Ingredients Ltd — Q4 FY26
Vidhi Specialty Food Ingredients reported FY26 revenue of ₹380 crore, marginally down from ₹382.3 crore due to global demand slowdown and tariff volatility.
✓ Verified against BSE filing
2-Min Summary
✦ AI-Generated from Full Transcript
Vidhi Specialty Food Ingredients reported FY26 revenue of ₹380 crore, marginally down from ₹382.3 crore due to global demand slowdown and tariff volatility. However, EBITDA grew 14.7% to ₹78 crore and PAT rose 20.8% to ₹49.15 crore, driven by product mix improvement and cost controls. EBITDA margin expanded 261 bps to 20.52%, with manufacturing sales margins at ~24-25%. Management guided for full capacity utilization in FY27 and expects value-added product contribution to double from 5% to 10-12%. A major capex of ₹75-85 crore is planned for new high-margin product lines, with commissioning in H2 FY28. The pharma coating range (Quote Icon) is in advanced sampling stages. Key risk: continued geopolitical disruptions in key export markets (Iran, Bangladesh, Philippines) could delay demand recovery.
Key Numbers
Manufacturing sales EBITDA margin
24-25%
+300-400bps YoY
EBITDA margin on manufacturing sales (₹330 crore) is significantly higher than blended margin, indicating core strength.
US export share
19%
0% YoY
US (including Canada) accounts for 19% of exports, not 44% as some analysts assumed; management clarified no FDA ban on synthetic colors.
New product capex
₹75-85 crore
New
Capex for new high-margin product line at Dhar; expected to generate ₹125-150 crore revenue in first phase, commissioning in H2 FY28.
Management Guidance
Full capacity utilization in FY27
Management expects full utilization of both Dhar and RoA facilities in FY27, driven by robust demand recovery.
Management guidance growthValue-added product contribution to double to 10-12% in FY27
Contribution of high-margin value-added products expected to rise from 5% to 10-12% in FY27, with potential for higher if approvals come through.
Management guidance growthCapex of ₹75-85 crore for new product line in FY27
Investment in new high-margin product line at Dhar, with commissioning expected in 18 months (H2 FY28). First phase revenue target of ₹125-150 crore.
Management guidance capexPharma coating (Quote Icon) sampling and approvals ongoing
Aggressive sampling with pharma companies; approval cycle ~6 months; initial feedback favorable.
Management guidance ai_strategyKey Risks
Geopolitical disruptions in key export markets
Markets like Iran, Bangladesh, and Philippines are severely impacted by geopolitical tensions, delaying demand recovery.
high · management_commentaryUS tariff volatility and demand uncertainty
Analyst raised concern about US tariff impact; management acknowledged volatility but noted US market has stabilized. However, further tariff changes could affect sales.
medium · analyst_questionWorking capital increase due to export finance subvention withdrawal
Interest cost increased due to withdrawal of export finance subvention by Indian government in December 2025, impacting finance costs.
medium · management_commentaryExecution risk on new product capex
Large capex of ₹75-85 crore for new product line may face delays or cost overruns; commissioning timeline of 18 months is ambitious.
medium · data_observationNotable Quotes
The manufacturing sales has been 330 crores from which most of this EBITDA margin has evolved. So if you see the actual EBITDA margin on manufactured sales it would be close to 24-25%.
The US was never planning to ban synthetic food colors. So that perception is completely false.
We have a existing business plan on which we are working commercializing these products which can be done every 18-24 months. We have a new pipeline of products that are being commercialized which leaves us with a very clear pathway of growth for a longer period of time, one whole decade from now.
Frequently Asked Questions
What was Vidhi Specialty Food's revenue in Q4 FY26?
Vidhi Specialty Food reported revenue of ₹123 Cr in Q4 FY26, representing a -0.6% change compared to the same quarter last year.
What guidance did Vidhi Specialty Food management give for FY27?
Full capacity utilization in FY27: Management expects full utilization of both Dhar and RoA facilities in FY27, driven by robust demand recovery. Value-added product contribution to double to 10-12% in FY27: Contribution of high-margin value-added products expected to rise from 5% to 10-12% in FY27, with potential for higher if approvals come through. Capex of ₹75-85 crore for new product line in FY27: Investment in new high-margin product line at Dhar, with commissioning expected in 18 months (H2 FY28). First phase revenue target of ₹125-150 crore. Pharma coating (Quote Icon) sampling and approvals ongoing: Aggressive sampling with pharma companies; approval cycle ~6 months; initial feedback favorable.
What are the key risks for Vidhi Specialty Food in FY27?
Key risks include Geopolitical disruptions in key export markets — Markets like Iran, Bangladesh, and Philippines are severely impacted by geopolitical tensions, delaying demand recovery.; US tariff volatility and demand uncertainty — Analyst raised concern about US tariff impact; management acknowledged volatility but noted US market has stabilized. However, further tariff changes could affect sales.; Working capital increase due to export finance subvention withdrawal — Interest cost increased due to withdrawal of export finance subvention by Indian government in December 2025, impacting finance costs.; Execution risk on new product capex — Large capex of ₹75-85 crore for new product line may face delays or cost overruns; commissioning timeline of 18 months is ambitious..
Did Vidhi Specialty Food meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Vidhi Specialty Food Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary verified against official BSE/NSE filings.